AI MARKET SCANNING

Enliven Therapeutics Inc

📅 Next Catalyst: Nov 11, 2026 (🌙 Close) 🏛️ NASDAQ 📁 Health Technology 🏭 Biotechnology
AVG HISTORICAL GAP +0.53%
MAX GAP RECORD +4.28%
🔒 PRO INSTITUTIONAL AI PREDICTIVE WIN RATE
94.2%
REVEAL PRO DIRECTION ⚡

SENTINEL HISTORICAL GAP VIEWER

// $ELVN
📊 1-YEAR TIMELINE (GAPS PLOTTED) 🔮 SIMULATE SETUP 🔒
Bullish Opening Gap Bearish Opening Gap T-1 Close Baseline

CATALYSTS & GAP HISTORY

Nov 11, 2026 Earnings Release 2026-11-11 (UNDETERMINED) 🔮 UPCOMING 🔒
Aug 12, 2026 Earnings Release 2026-08-12 (AFTER CLOSE)
+1.07%
May 13, 2026 Earnings Release 2026-05-13 (AFTER CLOSE)
+0.11%
Mar 03, 2026 Earnings Release 2026-03-03 (AFTER CLOSE)
-0.56%
Nov 12, 2025 Earnings Release 2025-11-12 (AFTER CLOSE)
+0.05%
Aug 13, 2025 Earnings Release 2025-08-13 (AFTER CLOSE)
-0.23%
May 14, 2025 Earnings Release 2025-05-14 (AFTER CLOSE)
-2.26%
Mar 13, 2025 Earnings Release 2025-03-13 (AFTER CLOSE)
+3.99%

VOLATILITY & GAP BIAS

AVG GAP MOVE 1.7%
Bullish Gaps (5)
Bearish Gaps (3)
Neutral / Flat (6)

QUANTITATIVE LIVE RADAR BLOTTER

Algorithmic execution stream for $ELVN

EXECUTIONS4 LOGS
STATUS🔒 ENCRYPTED
Execution Date Strategy & Setup Direction Execution Range Hold Time Net PnL
2026-10-29 🔒 PRO RADAR ••• x• $•••.•• → $•••.•• 219m +4.83%
••••-••-•• 🔒 LOCKED ••• x• $•••.•• → $•••.•• ••m +••.••%
••••-••-•• 🔒 LOCKED ••• x• $•••.•• → $•••.•• ••m +••.••%
••••-••-•• 🔒 LOCKED ••• x• $•••.•• → $•••.•• ••m +••.••%
🔒 Real-Time Strategy Telemetry Protected

Exact execution levels, Trailing Stops, and live bot signals are reserved for PRO members.

UNLOCK LIVE RADAR ⚡

📖 Intelligence Summary

Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery and development of small molecule therapeutics. Its pipeline includes BCR-ABL Program: ELVN-001and HER2 Program: ELVN-002. The company was founded by Samuel S. Kintz, Joseph P. Lyssikatos, and Anish Patel on June 1, 2019 and is headquartered in…

NEXT UPCOMING PREDICTIVE SIGNAL
STRONG BUY / TARGET +35%
🔓 REVEAL AI SIGNAL & TARGETS ↗